MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria
Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US
For people with relapsed or refractory diffuse large B-cell lymphoma
IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy
If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
Subscribe To Our Newsletter & Stay Updated
